Cumberland Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
CPIX Cumberland Pharmaceuticals Inc
GOL Gol Linhas Aereas Inteligentes SA
AAPL Apple Inc
JPM-L JPMorgan Chase & Co
BZFDW BuzzFeed Equity Warrant Exp 1st Dec 2026 *W EXP 12/01/2026
PANW Palo Alto Networks Inc
SIEGY Siemens AG
SLGL Sol Gel Technologies Ltd
AYRWF Ayr Wellness Inc
CTV Innovid Corp
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company that is focused on the acquisition, development, and commercialization of prescription pharmaceutical products. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever; Kristalose for oral solution, a prescription laxative, for the treatment of constipation; and Omeclamox-Pak for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease. Its brands also include RediTrex injection, for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis; Sancuso transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ injection.

Postmarket

Last Trade
Delayed
$2.76
0.03 (1.10%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$2.73
Day's Change
-0.005 (-0.18%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
2.78
Day's Low
2.70
Volume
(Light)
Volume:
3,648

10-day average volume:
9,296
3,648

CPIX's position in the Pharmaceuticals industry

Industry PeersCPIXPRTKAQSTADMPACRX

Summary

Company ProfileCumberland Pharmaceuticals Inc. is a specialty pharmaceutical company that is focused on the acquisition, development, and commercialization of prescription pharmaceutical products. Its portfolio of...
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases...
Go to PRTK summary
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered products to deliver molecules, providing alternatives to care therapies. It is...
Go to AQST summary
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company. The Company is focused on developing and commercializing products in various therapeutic areas, including allergy, opioid...
Go to ADMP summary
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. Its...
Go to ACRX summary
52-Week Change

VS. INDUSTRY
-21.41%
-44.03%
-67.04%
-67.08%
-78.39%
Market Cap

VS. INDUSTRY
$39.6M
$117.2M
$48.2M
$29.4M
$14.8M
Beta

VS. INDUSTRY
0.3
1.5
2.7
1.3
0.2
Dividend Yield

VS. INDUSTRY
--
--
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
--
--
--
--
0.32x
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$41.2M
$116.5M
$48.1M
$1.4M
$1.5M
Profit Margin

VS. INDUSTRY
-18.39%
-76.10%
-147.69%
-2,213.54%
3,111.24%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
--
--
--
--
--
Revenue Growth (TTM)

VS. INDUSTRY
8.65%
1.85%
2.50%
-66.27%
-57.20%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.